![](https://tracker.live.rns-distribution.com/track.live-rns/5278111_d9353a075fe0b610698e373da828b7e4.png)
RNS ANNOUNCEMENT
iShares plc (the "Company")
iShares MSCI Emerging Markets UCITS ETF USD (Dist)
iShares Core MSCI EM IMI UCITS ETF (the "Funds")
(ISIN(s) IE00B0M63177; IE00BD45KH83; IE00BKM4GZ66)
23rd July 2024
The Directors of the Company wish to advise you that, subject to the approval of the updated Prospectus by the Central Bank of Ireland, the index tracking investment strategy (and therefore the investment policy) of the Fund will be changed from non-replicating to replicating. Once approved by the Central Bank of Ireland, the effective date of this change will be published on an RNS (regulatory news service) announcement (the "Effective Date").
A new version of the Company's prospectus and Key Investor Information Document (KIID) will be published on or around the Effective Date, subject to the approval of the Central Bank of Ireland and will be available on www.ishares.com.
An electronic copy of the full shareholder letter shall be made available shortly for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism and available to download from the iShares website www.ishares.com
We understand that investors may have questions in relation to this event. If you have any queries, but you do not have a usual iShares contact, you can contact iShares in your respective region on the below contact numbers and email addresses:
· If located in United Kingdom or if located in elsewhere than the below, you can contact iShares at: info@ishares.co.uk, or the helpline telephone number: +44 207 743 1500
· If located in Germany, you can contact iShares at: info@iShares.de, or the helpline telephone number: +49 89 42729 5858
· If located in Switzerland, you can contact iShares at: iSharesSwitzerland@BlackRock.com, or the helpline telephone number 0800 33 66 88
-END-
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.